Community Health Department, Technical Institute of Karbala, AL-Furat Al-Awsat Technical University, Najaf, Iraq.
Department of Clinical Laboratory Sciences, College of Applied Medical Science, King Khalid University, Abha, Saudi Arabia.
Med Oncol. 2024 Apr 24;41(6):127. doi: 10.1007/s12032-024-02362-0.
Chimeric Antigen Receptor (CAR) based therapies are becoming increasingly important in treating patients. CAR-T cells have been shown to be highly effective in the treatment of hematological malignancies. However, harmful therapeutic barriers have been identified, such as the potential for graft-versus-host disease (GVHD), neurotoxicity, and cytokine release syndrome (CRS). As a result, CAR NK-cell therapy is expected to be a new therapeutic option. NK cells act as cytotoxic lymphocytes, supporting the innate immune response against autoimmune diseases and cancer cells by precisely detecting and eliminating malignant cells. Genetic modification of these cells provides a dual approach to the treatment of AD and cancer. It can be used through both CAR-independent and CAR-dependent mechanisms. The use of CAR-based cell therapies has been successful in treating cancer patients, leading to further investigation of this innovative treatment for alternative diseases, including AD. The complementary roles of CAR T and CAR NK cells have stimulated exploration in this area. Our study examines the latest research on the therapeutic effectiveness of these cells in treating both cancer and ADs.
嵌合抗原受体 (CAR) 疗法在治疗患者方面变得越来越重要。CAR-T 细胞已被证明在治疗血液系统恶性肿瘤方面非常有效。然而，已经确定了有害的治疗障碍，例如移植物抗宿主病 (GVHD)、神经毒性和细胞因子释放综合征 (CRS) 的风险。因此，CAR NK 细胞疗法有望成为一种新的治疗选择。NK 细胞作为细胞毒性淋巴细胞，通过精确地检测和消除恶性细胞，支持针对自身免疫性疾病和癌细胞的先天免疫反应。对这些细胞进行基因修饰为治疗 AD 和癌症提供了双重方法。它可以通过 CAR 独立和 CAR 依赖机制来使用。CAR 基于细胞疗法已成功用于治疗癌症患者，这促使人们进一步研究这种创新疗法在包括 AD 在内的其他疾病中的应用。CAR T 和 CAR NK 细胞的互补作用激发了该领域的探索。我们的研究检查了这些细胞在治疗癌症和 AD 方面的治疗效果的最新研究。
